Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free NKTR Stock Alerts

Nektar Therapeutics (NKTR) Financials

Nektar Therapeutics logo
$73.02 -2.90 (-3.82%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$73.26 +0.24 (+0.33%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Nektar Therapeutics

Annual Income Statements for Nektar Therapeutics

This table shows Nektar Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Consolidated Net Income / (Loss)		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Net Income / (Loss) Continuing Operations		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Total Pre-Tax Income 		-81 -153 -96 683 -440 -444 -523 -365 -276 -119 -155
Total Operating Income		 -29 -113 -60 688 -440 -425 -446 -376 -264 -105 -140
Total Gross Profit		 197 135 277 1,169 93 133 77 70 56 68 55
Total Revenue		 231 165 308 1,193 115 153 102 92 90 98 55
Operating Revenue		 231 165 308 1,193 115 153 102 92 90 98 55
Total Cost of Revenue		 34 30 31 24 21 19 25 22 34 31 0.00
Operating Cost of Revenue		 34 30 31 24 21 19 25 22 34 31 0.00
Total Operating Expenses		 226 248 337 481 533 559 523 447 320 173 195
Selling, General & Admin Expense		 43 44 52 81 99 105 123 92 77 77 69
Research & Development Expense		 183 204 268 400 435 409 400 218 114 121 117
Other Operating Expenses / (Income)		 - - - - - - - - 0.00 -40 0.00
Restructuring Charge		 - - - - - - 0.00 136 52 16 9.33
Total Other Income / (Expense), net		 -51 -40 -36 -5.21 -0.02 -19 -77 11 -13 -14 -15
Interest Expense		 53 42 41 43 46 37 47 29 25 28 26
Interest & Investment Income		 - - - - - - 2.73 6.78 19 15 10
Other Income / (Expense), net		 1.68 2.39 4.52 38 46 18 -33 33 -6.25 -0.39 0.36
Income Tax Expense		 0.51 0.88 0.62 1.41 0.61 0.49 0.56 3.22 -0.20 -0.24 -0.14
Other Gains / (Losses), net		 - - - - - - - - - 0.00 -8.73
Basic Earnings per Share		 ($0.61) ($1.10) ($0.62) $4.02 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($8.68) ($9.73)
Weighted Average Basic Shares Outstanding		 132.46M 139.60M 155.95M 169.60M 174.99M 178.58M 183.30M 187.14M 190.00M 13.71M 16.87M
Diluted Earnings per Share		 ($0.61) ($1.10) ($0.62) $3.78 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($8.68) ($9.73)
Weighted Average Diluted Shares Outstanding		 132.46M 139.60M 155.95M 180.12M 174.99M 178.58M 183.30M 187.14M 190.00M 13.71M 16.87M
Weighted Average Basic & Diluted Shares Outstanding		 132.46M 139.60M 156M 169.50M 177.56M 182.18M 186.27M 189.24M 183.62M 186.10M 28.69M

Quarterly Income Statements for Nektar Therapeutics

This table shows Nektar Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -42 -37 -52 -37 7.26 -51 -42 -36 -36 -45 -41
Consolidated Net Income / (Loss)		 -42 -37 -52 -37 7.26 -51 -42 -36 -36 -45 -41
Net Income / (Loss) Continuing Operations		 -42 -37 -52 -37 7.26 -51 -42 -36 -36 -45 -41
Total Pre-Tax Income 		-42 -37 -52 -37 7.00 -46 -39 -35 -35 -43 -40
Total Operating Income		 -34 -35 -50 -34 14 -45 -36 -32 -28 -39 -42
Total Gross Profit		 17 13 14 20 21 10 11 12 22 11 10
Total Revenue		 24 22 23 24 29 10 11 12 22 11 10
Operating Revenue		 24 22 23 24 29 10 11 12 22 11 10
Total Cost of Revenue		 7.28 8.53 9.74 4.44 7.98 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 50 49 64 54 6.85 55 47 43 49 50 52
Selling, General & Admin Expense		 17 20 21 19 17 24 17 16 11 13 13
Research & Development Expense		 30 27 30 35 29 30 30 27 30 36 39
Restructuring Charge		 2.85 0.98 13 0.05 1.36 0.17 0.45 0.14 8.58 0.80 0.58
Total Other Income / (Expense), net		 -8.60 -1.41 -2.54 -2.70 -7.35 -1.83 -3.17 -3.35 -7.04 -4.04 2.04
Interest Expense		 6.87 5.53 6.41 6.02 10 4.97 5.39 6.05 9.77 7.94 7.21
Interest & Investment Income		 4.62 4.22 3.90 3.44 2.94 2.87 1.97 2.82 2.78 4.24 9.35
Other Income / (Expense), net		 -6.35 -0.10 -0.04 -0.12 -0.14 0.27 0.26 -0.12 -0.04 -0.34 -0.10
Income Tax Expense		 -0.03 -0.04 0.05 0.01 -0.26 0.05 -0.19 -0.03 0.03 0.06 0.00
Other Gains / (Losses), net		 - 0.00 0.00 0.00 - -4.46 -2.39 -0.53 -1.35 -1.75 -0.32
Basic Earnings per Share		 ($0.21) ($0.19) ($3.76) ($2.66) $0.04 ($3.62) ($2.95) ($1.87) ($2.14) ($1.82) ($1.23)
Weighted Average Basic Shares Outstanding		 190.00M 194.75M 13.92M 13.95M 205.66M 14.06M 14.09M 18.95M 16.87M 24.74M 33.05M
Diluted Earnings per Share		 ($0.21) ($0.19) ($3.76) ($2.66) $0.04 ($3.62) ($2.95) ($1.87) ($2.14) ($1.82) ($1.23)
Weighted Average Diluted Shares Outstanding		 190.00M 194.75M 13.92M 13.95M 205.66M 14.06M 14.09M 18.95M 16.87M 24.74M 33.05M
Weighted Average Basic & Diluted Shares Outstanding		 183.62M 183.62M 184.08M 184.46M 186.10M 186.10M 19.02M 20.34M 28.69M 33.79M 34.14M

Annual Cash Flow Statements for Nektar Therapeutics

This table details how cash moves in and out of Nektar Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 43 4.07 -55 190 -99 103 -174 63 -53 8.98 -29
Net Cash From Operating Activities		 -73 -117 -80 718 -329 -313 -413 -304 -193 -176 -209
Net Cash From Continuing Operating Activities		 -73 -117 -80 718 -329 -313 -413 -304 -193 -176 -209
Net Income / (Loss) Continuing Operations		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Consolidated Net Income / (Loss)		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Depreciation Expense		 13 15 15 11 13 14 14 13 7.82 4.39 1.03
Amortization Expense		 - - - - -11 3.94 6.73 -2.44 -15 -9.25 -5.51
Non-Cash Adjustments To Reconcile Net Income		 30 13 39 65 102 99 116 48 102 -59 -18
Changes in Operating Assets and Liabilities, net		 -35 7.93 -38 -39 8.60 14 -25 5.88 -11 6.67 -22
Net Cash From Investing Activities		 -14 -82 -29 -1,380 207 496 203 366 140 143 -1.20
Net Cash From Continuing Investing Activities		 -14 -82 -29 -1,380 207 496 203 366 140 143 -1.20
Purchase of Property, Plant & Equipment		 -11 -6.39 -9.68 -14 -26 -7.26 -15 -5.68 -0.87 -1.47 -0.17
Purchase of Investments		 -298 -335 -404 -2,271 -1,381 -988 -961 -468 -512 -262 -285
Sale and/or Maturity of Investments		 269 259 385 903 1,614 1,491 1,178 826 651 340 285
Other Investing Activities, net		 25 - - - - - - - 0.00 65 -0.70
Net Cash From Financing Activities		 131 204 54 852 23 -80 36 1.51 0.03 42 181
Net Cash From Continuing Financing Activities		 131 204 54 852 23 -80 36 1.51 0.03 42 181
Repurchase of Common Equity		 - - - - - - - - 0.00 -3.00 -1.15
Issuance of Common Equity		 32 210 60 852 23 23 33 0.76 0.03 30 182
Other Financing Activities, net		 - - - 0.00 0.00 146 3.00 0.75 0.00 15 0.00
Effect of Exchange Rate Changes		 -0.16 - -0.05 - -0.10 0.02 -0.09 -0.33 0.06 -0.00 0.01
Cash Income Taxes Paid		 0.86 0.76 0.56 0.62 0.56 0.54 0.33 0.27 2.66 0.08 -0.20

Quarterly Cash Flow Statements for Nektar Therapeutics

This table details how cash moves in and out of Nektar Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -30 13 -21 2.17 14 -5.36 4.09 -1.96 -26 134 -113
Net Cash From Operating Activities		 -47 -48 -38 -44 -46 -49 -46 -49 -65 -44 -76
Net Cash From Continuing Operating Activities		 -47 -48 -38 -44 -46 -49 -46 -49 -65 -44 -79
Net Income / (Loss) Continuing Operations		 -42 -37 -52 -37 7.26 -51 -42 -36 -36 -45 -41
Consolidated Net Income / (Loss)		 -42 -37 -52 -37 7.26 -51 -42 -36 -36 -45 -41
Depreciation Expense		 1.65 1.61 1.46 0.99 0.33 0.43 0.21 0.20 0.19 0.15 0.16
Amortization Expense		 - -3.06 -2.58 -2.06 - -1.32 -0.87 -1.43 -1.89 -1.66 -3.57
Non-Cash Adjustments To Reconcile Net Income		 8.48 -5.93 3.69 -10 -38 1.06 -3.68 -5.66 -9.81 -0.22 -6.83
Changes in Operating Assets and Liabilities, net		 -0.25 -3.70 12 4.49 -6.22 1.67 0.19 -6.34 -17 2.34 -28
Net Cash From Investing Activities		 17 19 17 46 60 44 50 -95 0.37 -351 -399
Net Cash From Continuing Investing Activities		 17 19 17 46 60 44 50 -95 0.37 -351 -399
Purchase of Property, Plant & Equipment		 -0.24 -0.16 -0.19 -0.67 -0.46 -0.00 -0.04 -0.11 -0.02 -0.02 -0.09
Purchase of Investments		 -139 -105 -68 -18 -70 -25 -19 -150 -92 -452 -535
Sale and/or Maturity of Investments		 156 124 86 65 65 69 69 55 92 101 136
Net Cash From Financing Activities		 0.01 42 0.02 0.01 0.08 0.01 0.21 142 39 530 365
Net Cash From Continuing Financing Activities		 0.01 42 0.02 0.01 0.08 0.01 0.21 142 39 530 365
Repurchase of Common Equity		 - -3.00 - - - 0.00 - -1.15 - -0.03 -1.21
Issuance of Common Equity		 0.01 30 0.02 0.01 0.08 0.01 0.21 143 39 530 366

Annual Balance Sheets for Nektar Therapeutics

This table presents Nektar Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 499 569 509 2,150 1,977 1,539 1,117 711 398 304 280
Total Current Assets		 350 426 327 1,438 1,422 1,138 796 546 331 261 266
Cash & Equivalents		 56 60 4.76 195 96 199 25 88 35 44 15
Short-Term Investments		 253 329 291 1,140 1,228 863 709 417 268 211 231
Other Current Assets		 9.81 10 15 48 47 22 23 16 9.78 6.07 21
Plant, Property, & Equipment, net		 71 66 47 49 66 60 61 32 19 3.41 0.00
Total Noncurrent Assets		 77 77 135 664 490 341 261 132 48 39 14
Long-Term Investments		 - 0.00 57 583 279 137 65 0.00 26 26 0.00
Other Noncurrent Operating Assets		 0.75 0.82 0.99 4.24 135 128 120 56 23 13 14
Total Liabilities & Shareholders' Equity		 499 569 509 2,150 1,977 1,539 1,117 711 398 304 280
Total Liabilities		 492 481 421 433 572 461 438 344 267 243 191
Total Current Liabilities		 61 72 56 82 354 116 85 68 51 61 54
Accounts Payable		 2.36 2.82 4.78 5.85 19 22 9.75 13 9.85 12 11
Accrued Expenses		 12 13 20 48 52 65 42 37 22 30 22
Other Current Liabilities		 10 20 0.45 0.49 13 - 17 19 - 20 20
Total Noncurrent Liabilities		 431 409 365 351 218 346 352 276 216 182 137
Other Noncurrent Operating Liabilities		 126 113 101 93 216 346 352 276 216 182 137
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.43 88 88 1,718 1,405 1,077 680 367 131 61 90
Total Preferred & Common Equity		 6.43 88 88 1,718 1,405 1,077 680 367 131 61 90
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 6.43 88 88 1,718 1,405 1,077 680 367 131 61 90
Common Stock		 1,876 2,111 2,208 3,148 3,271 3,389 3,517 3,575 3,608 3,660 3,850
Retained Earnings		 -1,867 -2,021 -2,118 -1,424 -1,865 -2,309 -2,833 -3,201 -3,477 -3,596 -3,760
Treasury Stock		 - - - - - - - - 0.00 -3.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -2.17 -2.36 -2.11 -6.32 -1.01 -2.30 -4.16 -6.91 0.08 0.06 0.02

Quarterly Balance Sheets for Nektar Therapeutics

This table presents Nektar Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 494 442 396 343 308 256 208 301 763 1,095
Total Current Assets		 441 399 320 295 286 230 187 281 589 739
Cash & Equivalents		 51 65 49 28 30 39 43 41 150 39
Short-Term Investments		 359 308 241 243 214 180 133 229 419 645
Other Current Assets		 9.60 9.03 11 8.29 8.93 11 11 11 20 55
Plant, Property, & Equipment, net		 23 20 17 15 3.60 3.16 2.99 2.83 0.00 0.00
Total Noncurrent Assets		 31 23 59 33 18 23 18 17 174 356
Long-Term Investments		 - - 37 19 4.54 9.78 5.37 4.84 163 339
Other Noncurrent Operating Assets		 31 23 22 14 13 13 13 12 11 17
Total Liabilities & Shareholders' Equity		 494 442 396 343 308 256 208 301 763 1,095
Total Liabilities		 297 283 269 264 259 243 232 216 187 192
Total Current Liabilities		 51 52 52 57 68 71 71 66 58 71
Accounts Payable		 2.62 3.29 8.76 6.48 8.58 18 14 16 10 25
Accrued Expenses		 29 30 24 30 32 31 35 29 25 23
Other Current Liabilities		 19 19 19 21 22 - 22 - 23 23
Total Noncurrent Liabilities		 247 231 217 206 191 172 160 150 129 121
Other Noncurrent Operating Liabilities		 247 231 217 206 191 172 160 150 129 121
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 197 159 127 80 49 14 -24 85 576 903
Total Preferred & Common Equity		 197 159 127 80 49 14 -24 85 576 903
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 197 159 127 80 49 14 -24 85 576 903
Common Stock		 3,593 3,601 3,644 3,650 3,655 3,664 3,667 3,809 4,382 4,751
Retained Earnings		 -3,389 -3,435 -3,514 -3,566 -3,603 -3,647 -3,689 -3,724 -3,805 -3,846
Treasury Stock		 - - -3.00 -3.00 -3.00 -3.00 -3.00 0.00 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -6.45 -6.35 -0.40 -0.49 0.36 0.04 -0.01 0.06 -1.03 -1.76

Annual Metrics And Ratios for Nektar Therapeutics

This table displays calculated financial ratios and metrics derived from Nektar Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 133,451,372.00 152,835,294.00 157,467,703.00 173,085,231.00 175,922,206.00 179,398,666.00 184,557,124.00 187,954,482.00 190,770,566.00 - 20,341,589.00
DEI Adjusted Shares Outstanding		 8,896,758.00 10,189,020.00 10,497,847.00 11,539,015.00 11,728,147.00 11,959,911.00 12,303,808.00 12,530,299.00 12,718,038.00 - 20,341,589.00
DEI Earnings Per Adjusted Shares Outstanding		 -9.12 -15.07 -9.21 59.04 -37.57 -37.16 -42.58 -29.38 -21.71 - -8.07
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -21 -79 -42 687 -308 -298 -312 -263 -185 -74 -98
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -122.85% -121.24% -109.17%
Earnings before Interest and Taxes (EBIT)		 -28 -110 -55 726 -394 -407 -479 -343 -270 -106 -140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -95 -40 736 -392 -389 -458 -332 -277 -110 -144
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -56 -76 -79 620 -312 -136 -300 -244 -144 -32 -159
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -51 -53 -16 50 54 -107 -119 -138 -179 -221 -159
Increase / (Decrease) in Invested Capital		 35 -2.53 37 66 3.82 -162 -12 -19 -41 -41 61
Book Value per Share		 $0.05 $0.58 $0.56 $9.92 $7.99 $6.01 $3.68 $1.95 $0.69 $0.33 $4.42
Tangible Book Value per Share		 ($0.53) $0.08 $0.07 $9.48 $7.55 $5.58 $3.27 $1.54 $0.69 $0.33 $4.42
Total Capital		 254 332 333 1,965 1,658 1,091 680 367 150 61 90
Total Debt		 248 243 245 247 253 14 0.00 0.00 19 0.00 0.00
Total Long-Term Debt		 243 243 245 247 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -61 -146 -108 -1,671 -1,351 -1,185 -799 -505 -310 -281 -249
Capital Expenditures (CapEx)		 11 6.39 9.68 12 26 7.26 15 -7.52 -0.38 1.47 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -35 -25 20 -4.31 -26 -24 -27 -4.93 -55 -33
Debt-free Net Working Capital (DFNWC)		 294 354 271 1,356 1,321 1,036 710 478 299 200 213
Net Working Capital (NWC)		 289 354 271 1,356 1,068 1,022 710 478 279 200 213
Net Nonoperating Expense (NNE)		 61 75 55 5.20 133 147 212 105 91 45 66
Net Nonoperating Obligations (NNO)		 -57 -141 -104 -1,667 -1,351 -1,185 -799 -505 -310 -281 -249
Total Depreciation and Amortization (D&A)		 13 15 15 11 1.76 18 21 11 -7.04 -4.85 -4.49
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.61) ($1.10) ($0.62) $4.02 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($0.58) ($9.73)
Adjusted Weighted Average Basic Shares Outstanding		 135.94M 153.83M 160.92M 169.60M 174.99M 178.58M 183.30M 187.14M 190.00M 205.66M 16.87M
Adjusted Diluted Earnings per Share		 ($0.61) ($1.10) ($0.62) $3.78 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($0.58) ($9.73)
Adjusted Weighted Average Diluted Shares Outstanding		 135.94M 153.83M 160.92M 180.12M 174.99M 178.58M 183.30M 187.14M 190.00M 205.66M 16.87M
Adjusted Basic & Diluted Earnings per Share		 ($0.61) ($1.10) ($0.62) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 132.46M 139.60M 155.95M 174.10M 177.56M 182.18M 186.27M 189.24M 183.62M 186.10M 28.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -79 -31 687 -308 -266 -312 -168 -95 -63 -92
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Nektar Therapeutics

This table displays calculated financial ratios and metrics derived from Nektar Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 190,770,566.00 183,617,817.00 183,624,620.00 184,079,479.00 - 186,103,588.00 186,103,588.00 19,018,573.00 20,341,589.00 28,687,963.00 33,786,032.00
DEI Adjusted Shares Outstanding		 12,718,038.00 12,241,188.00 12,241,641.00 12,271,965.00 - 12,406,906.00 12,406,906.00 19,018,573.00 20,341,589.00 28,687,963.00 33,786,032.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.31 -3.01 -4.28 -3.02 - -4.10 -3.35 -1.87 -1.77 -1.57 -1.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.45% 0.21% 14.59% -0.08% 22.15% -51.66% -52.42% -51.13% - 3.83% -9.34%
EBITDA Growth		 27.84% 72.13% -6.79% 18.32% 138.07% -22.13% 28.09% 7.05% - 9.44% -25.20%
EBIT Growth		 28.98% 73.69% 0.11% 23.75% 135.66% -24.61% 27.79% 7.75% - 11.02% -17.99%
NOPAT Growth		 36.13% 73.70% 1.63% 23.45% 163.43% -25.71% 27.21% 7.78% - 12.31% -16.87%
Net Income Growth		 29.50% 73.14% -2.43% 19.15% 117.26% -38.26% 20.57% 4.14% - 11.75% 2.33%
EPS Growth		 34.38% 73.97% -2.43% 19.15% 119.05% -26.32% 21.54% 29.70% - 49.72% 58.31%
Operating Cash Flow Growth		 18.47% 7.76% 26.82% -4.30% 1.83% -2.43% -21.31% -10.99% - 9.69% -65.66%
Free Cash Flow Firm Growth		 198.49% -192.60% -582.11% -119.39% 223.36% 9.15% 15.22% -791.04% - -72.04% -272.53%
Invested Capital Growth		 -29.53% 7.71% 0.72% -6.93% -23.09% 3.25% 2.59% 26.44% - 19.42% 41.46%
Revenue Q/Q Growth		 -1.07% -9.40% 8.55% 2.70% 20.94% -64.15% 6.84% 5.50% - -50.19% -6.72%
EBITDA Q/Q Growth		 12.18% 3.20% -37.73% 30.23% 143.45% -410.53% 18.91% 9.82% - -39.09% -12.11%
EBIT Q/Q Growth		 11.82% 10.87% -40.21% 30.81% 141.24% -411.47% 18.75% 11.61% - -42.16% -7.75%
NOPAT Q/Q Growth		 25.31% -5.72% -40.50% 31.00% 161.89% -309.52% 18.65% 12.58% - -41.17% -8.42%
Net Income Q/Q Growth		 8.20% 12.54% -42.28% 29.23% 119.59% -800.76% 18.26% 14.60% - -24.46% 9.54%
EPS Q/Q Growth		 12.50% 9.52% -42.28% 29.23% 122.22% -700.00% -1,129.17% 36.61% - 14.95% 32.42%
Operating Cash Flow Q/Q Growth		 -11.69% -1.79% 21.27% -16.52% -5.13% -6.21% 6.76% -6.61% - 31.81% -71.05%
Free Cash Flow Firm Q/Q Growth		 -63.54% -338.24% 12.27% 74.55% 707.85% -166.94% 18.14% -167.52% - 22.90% -77.27%
Invested Capital Q/Q Growth		 15.99% -11.23% -5.84% -8.12% 3.29% 12.58% -6.56% 18.35% - 0.35% 22.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 69.51% 60.56% 58.53% 81.62% 72.66% 100.00% 100.00% 100.00% - 100.00% 100.00%
EBITDA Margin		 -159.96% -170.90% -216.85% -147.31% 49.85% -431.81% -327.74% -280.15% - -376.60% -452.62%
Operating Margin		 -140.30% -163.72% -211.90% -142.37% 49.18% -425.76% -324.21% -268.63% - -359.58% -417.94%
EBIT Margin		 -166.87% -164.18% -212.06% -142.87% 48.72% -423.22% -321.88% -269.66% - -362.67% -418.92%
Profit (Net Income) Margin		 -176.17% -170.07% -222.93% -153.61% 24.89% -486.44% -372.20% -301.29% - -413.44% -400.97%
Tax Burden Percent		 99.93% 99.91% 100.09% 100.02% 103.70% 109.73% 105.58% 101.43% - 104.21% 100.80%
Interest Burden Percent		 105.65% 103.69% 105.03% 107.49% 49.26% 104.74% 109.52% 110.15% - 109.39% 94.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% -3.70% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -110.95% -95.68% -128.02% -161.63% -124.10% -189.46% -440.80% -180.24% - -53.60% -35.76%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Return on Assets (OROA)		 -27.13% -30.91% -47.17% -35.47% 13.66% -113.22% -87.57% -55.41% - -39.58% -35.11%
Return on Assets (ROA)		 -28.64% -32.02% -49.59% -38.14% 6.98% -130.14% -101.26% -61.91% - -45.12% -33.61%
Return on Common Equity (ROCE)		 -110.95% -95.68% -128.02% -161.63% -124.10% -189.46% -440.80% -180.24% - -53.60% -35.76%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -138.78% 0.00% 0.00% 0.00% -968.42% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -23 -25 -35 -24 15 -31 -25 -22 -19 -27 -30
NOPAT Margin		 -98.21% -114.60% -148.33% -99.66% 51.00% -298.04% -226.94% -188.04% - -251.71% -292.55%
Net Nonoperating Expense Percent (NNEP)		 -4.57% -3.07% -5.01% -4.01% -2.58% -7.40% -6.88% -5.04% - -3.74% -1.82%
Return On Investment Capital (ROIC_SIMPLE)		 -15.61% -19.57% -43.72% -49.18% 24.50% -87.62% 104.75% -20.67% -21.56% -4.74% -3.28%
Cost of Revenue to Revenue		 30.49% 39.44% 41.47% 18.38% 27.34% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 72.51% 93.11% 87.32% 78.58% 58.73% 232.75% 152.77% 136.30% - 123.74% 126.00%
R&D to Revenue		 125.36% 126.66% 126.54% 145.21% 98.53% 291.40% 267.44% 231.15% - 328.51% 386.23%
Operating Expenses to Revenue		 209.81% 224.28% 270.44% 223.98% 23.48% 525.76% 424.21% 368.63% - 459.58% 517.94%
Earnings before Interest and Taxes (EBIT)		 -40 -36 -50 -34 14 -44 -36 -32 -28 -39 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -38 -37 -51 -36 15 -45 -37 -33 -29 -41 -46
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.82 1.35 2.86 4.90 2.82 9.21 0.00 12.72 - 3.58 2.61
Price to Tangible Book Value (P/TBV)		 0.82 1.35 2.86 4.90 2.82 9.21 0.00 12.72 - 3.58 2.61
Price to Revenue (P/Rev)		 1.20 1.90 2.44 2.57 1.74 1.45 4.28 17.29 - 37.10 43.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 1.86 13.25 - 23.95 24.46
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.15 0.00 0.00 0.00 0.00 1.59 0.00 0.26 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -1.64 -2.13 -2.53 -3.12 -3.09 -3.79 -8.51 -3.95 - -1.59 -1.37
Leverage Ratio		 2.23 2.61 3.03 3.60 3.66 4.64 9.93 4.55 - 1.73 1.48
Compound Leverage Factor		 2.35 2.70 3.18 3.87 1.80 4.86 10.88 5.01 - 1.89 1.41
Debt to Total Capital		 12.82% 0.00% 0.00% 0.00% 0.00% 61.39% 0.00% 20.68% - 0.00% 0.00%
Short-Term Debt to Total Capital		 12.82% 0.00% 0.00% 0.00% 0.00% 61.39% 0.00% 20.68% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 87.18% 100.00% 100.00% 100.00% 100.00% 38.61% 100.00% 79.32% - 100.00% 100.00%
Debt to EBITDA		 -0.07 0.00 0.00 0.00 0.00 -0.18 0.00 -0.22 - 0.00 0.00
Net Debt to EBITDA		 1.12 0.00 0.00 0.00 0.00 1.74 0.00 2.48 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 -0.10 0.00 0.00 0.00 0.00 -0.27 0.00 -0.32 - 0.00 0.00
Net Debt to NOPAT		 1.68 0.00 0.00 0.00 0.00 2.58 0.00 3.68 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 -11.25 -11.30 -13.40 -15.04 -14.88 -19.10 -23.60 -13.58 - 0.38 3.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.45 6.10 5.15 4.24 4.26 3.24 2.61 4.24 - 10.21 10.42
Quick Ratio		 5.95 5.59 4.75 3.62 4.16 3.08 2.46 4.07 - 9.85 9.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 17 -41 -36 -9.26 56 -38 -31 -82 -81 -65 -115
Operating Cash Flow to CapEx		 -19,851.05% -30,501.91% -20,269.89% -6,596.40% -10,062.53% -2,452,650.00% -123,616.22% -42,772.81% - -246,100.00% -80,606.38%
Free Cash Flow to Firm to Interest Expense		 2.53 -7.49 -5.67 -1.54 5.54 -7.57 -5.72 -13.64 - -8.16 -15.94
Operating Cash Flow to Interest Expense		 -6.85 -8.66 -5.88 -7.30 -4.55 -9.86 -8.48 -8.06 - -5.58 -10.51
Operating Cash Flow Less CapEx to Interest Expense		 -6.89 -8.69 -5.91 -7.41 -4.59 -9.86 -8.49 -8.08 - -5.58 -10.53
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.16 0.19 0.22 0.25 0.28 0.27 0.27 0.21 - 0.11 0.08
Accounts Receivable Turnover		 25.08 27.27 73.61 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 1.91 1.93 2.16 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 3.51 4.05 4.94 7.91 8.84 8.46 8.25 19.47 - 0.00 0.00
Accounts Payable Turnover		 2.96 5.66 8.35 5.06 2.87 1.67 1.20 0.66 - 0.00 0.00
Days Sales Outstanding (DSO)		 14.55 13.38 4.96 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 190.80 188.87 168.89 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 123.37 64.49 43.69 72.20 127.32 219.07 305.19 552.28 - 0.00 0.00
Cash Conversion Cycle (CCC)		 81.97 137.77 130.15 -72.20 -127.32 -219.07 -305.19 -552.28 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -179 -199 -211 -228 -221 -193 -205 -168 -159 -155 -120
Invested Capital Turnover		 -0.57 -0.43 -0.44 -0.42 -0.49 -0.45 -0.36 -0.32 - -0.32 -0.34
Increase / (Decrease) in Invested Capital		 -41 17 1.52 -15 -41 6.48 5.47 60 61 37 85
Enterprise Value (EV)		 -202 -154 -63 -9.73 -110 -80 139 829 - 1,333 1,335
Market Capitalization		 108 172 228 239 172 127 321 1,082 - 2,064 2,359
Book Value per Share		 $0.69 $0.69 $0.43 $0.27 $0.33 $0.07 ($0.13) $4.47 $4.42 $20.09 $26.73
Tangible Book Value per Share		 $0.69 $0.69 $0.43 $0.27 $0.33 $0.07 ($0.13) $4.47 $4.42 $20.09 $26.73
Total Capital		 150 127 80 49 61 36 -24 107 90 576 903
Total Debt		 19 0.00 0.00 0.00 0.00 22 0.00 22 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -310 -326 -291 -249 -281 -207 -181 -253 -249 -732 -1,023
Capital Expenditures (CapEx)		 0.24 0.16 0.19 0.67 0.46 0.00 0.04 0.11 0.02 0.02 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.93 -22 -33 -26 -55 -38 -61 -33 -33 -37 -16
Debt-free Net Working Capital (DFNWC)		 299 267 238 219 200 181 115 237 213 531 668
Net Working Capital (NWC)		 279 267 238 219 200 159 115 215 213 531 668
Net Nonoperating Expense (NNE)		 19 12 18 13 7.62 20 16 13 17 18 11
Net Nonoperating Obligations (NNO)		 -310 -326 -291 -277 -281 -207 -181 -253 -249 -732 -1,023
Total Depreciation and Amortization (D&A)		 1.65 -1.46 -1.13 -1.07 0.33 -0.90 -0.66 -1.24 -1.70 -1.51 -3.41
Debt-free, Cash-free Net Working Capital to Revenue		 -5.46% -24.19% -35.82% -27.48% -56.22% -43.33% -81.04% -52.73% - -66.99% -29.17%
Debt-free Net Working Capital to Revenue		 331.43% 296.59% 255.33% 235.03% 203.09% 207.25% 153.70% 378.91% - 955.07% 1,224.45%
Net Working Capital to Revenue		 310.06% 296.59% 255.33% 235.03% 203.09% 182.22% 153.70% 343.48% - 955.07% 1,224.45%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.21) ($0.19) ($3.75) ($2.70) $0.04 ($0.24) ($2.95) ($1.87) ($2.14) ($1.82) ($1.23)
Adjusted Weighted Average Basic Shares Outstanding		 190.00M 194.75M 13.92M 13.95M 205.66M 210.92M 14.09M 18.95M 16.87M 24.74M 33.05M
Adjusted Diluted Earnings per Share		 ($0.21) ($0.19) ($3.75) ($2.70) $0.04 ($0.24) ($2.95) ($1.87) ($2.14) ($1.82) ($1.23)
Adjusted Weighted Average Diluted Shares Outstanding		 190.00M 194.75M 13.92M 13.95M 205.66M 210.92M 14.09M 18.95M 16.87M 24.74M 33.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($2.14) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 183.62M 183.62M 12.27M 12.30M 186.10M 186.10M 19.02M 20.34M 28.69M 33.79M 34.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -24 -26 -24 11 -31 -25 -22 -13 -27 -29
Normalized NOPAT Margin		 -89.86% -111.45% -108.73% -99.52% 37.69% -296.90% -224.14% -187.21% - -246.58% -288.56%
Pre Tax Income Margin		 -176.29% -170.23% -222.73% -153.57% 24.00% -443.30% -352.53% -297.04% - -396.74% -397.80%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.80 -6.42 -7.77 -5.73 1.40 -8.90 -6.67 -5.26 - -4.96 -5.89
NOPAT to Interest Expense		 -3.42 -4.48 -5.44 -3.99 1.47 -6.27 -4.70 -3.67 - -3.44 -4.11
EBIT Less CapEx to Interest Expense		 -5.84 -6.45 -7.80 -5.84 1.35 -8.90 -6.68 -5.28 - -4.96 -5.90
NOPAT Less CapEx to Interest Expense		 -3.45 -4.51 -5.47 -4.10 1.42 -6.27 -4.71 -3.69 - -3.44 -4.13
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% -1.71% -1.69% -1.78% -2.52% 0.00% 0.00% -0.95% - -0.74% -1.52%

Financials Breakdown Chart

Key Financial Trends

Nektar Therapeutics (NASDAQ: NKTR) shows a much stronger liquidity position today than it did a year ago, but the business is still deeply unprofitable and heavily dependent on financing activity. The most recent quarter suggests the company has a large cash cushion, yet operating losses remain wide and shares outstanding have surged, which is a major consideration for retail investors.

  • Cash and investments increased sharply in Q1 2026. NKTR ended the quarter with $149.6 million in cash and equivalents, $419.0 million in short-term investments, and $163.0 million in long-term investments, giving it substantial liquidity.
  • Total current assets improved to $589.0 million. That is a strong balance sheet buffer versus the company’s $57.7 million in current liabilities.
  • Operating revenue held up year over year. Q1 2026 revenue was $10.9 million, slightly above $10.5 million in Q1 2025.
  • Q1 2026 financing activity added significant cash. The company raised $529.6 million from issuance of common equity during the quarter, which largely explains the jump in cash and investments.
  • Investment income helped offset losses somewhat. In Q1 2026, interest and investment income was $4.2 million, which partially softened the impact of operating losses.
  • Debt is not the main issue, but obligations still matter. The balance sheet shows no short-term debt in Q1 2026, but it does carry $129.3 million in noncurrent liabilities.
  • Gross margin remains structurally favorable on revenue lines. NKTR reported no cost of revenue in Q1 2026, so the issue is not gross profit but operating expense burden.
  • Operating losses remain severe. Q1 2026 operating loss was $39.1 million, and net loss was $44.9 million.
  • Cash burn from operations continues. NKTR used $44.3 million in operating cash flow in Q1 2026, continuing a multi-quarter pattern of negative operating cash flow.
  • Share dilution has been extreme. Weighted average basic shares in Q1 2026 were 24.7 million, up sharply from 14.1 million in Q2 2025 and far below the much larger share counts seen in earlier periods due to restructuring and capital actions. This makes per-share metrics harder to improve.

Longer-term trend: NKTR’s revenue has generally hovered in the low-to-mid $10 million range in recent quarters, while operating expenses have stayed much higher, leading to recurring losses. The company has also relied on investment sales and equity issuance to fund operations. That means the near-term story is less about earnings growth and more about whether management can preserve cash while advancing the pipeline.

Bottom line: Nektar Therapeutics appears liquid enough to keep operating for now, but its financial profile still looks speculative. The balance sheet is stronger than before, yet persistent losses, negative operating cash flow, and dilution remain the biggest risks for shareholders.

08/15/26 12:33 AM ETAI Generated. May Contain Errors.

Nektar Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nektar Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Nektar Therapeutics' net income appears to be on an upward trend, with a most recent value of -$164.08 million in 2025, rising from -$81.18 million in 2015. The previous period was -$118.96 million in 2024. See where experts think Nektar Therapeutics is headed by visiting Nektar Therapeutics' forecast page.

Nektar Therapeutics' total operating income in 2025 was -$140.10 million, based on the following breakdown:
  • Total Gross Profit: $55.23 million
  • Total Operating Expenses: $195.33 million

Over the last 10 years, Nektar Therapeutics' total revenue changed from $230.78 million in 2015 to $55.23 million in 2025, a change of -76.1%.

Nektar Therapeutics' total liabilities were at $190.57 million at the end of 2025, a 21.6% decrease from 2024, and a 61.3% decrease since 2015.

In the past 10 years, Nektar Therapeutics' cash and equivalents has ranged from $4.76 million in 2017 to $198.96 million in 2020, and is currently $15.12 million as of their latest financial filing in 2025.

Over the last 10 years, Nektar Therapeutics' book value per share changed from 0.05 in 2015 to 4.42 in 2025, a change of 9,062.2%.


Related Companies

Financial statements for NASDAQ:NKTR last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel